Pediatric Research

Many drugs which have been used for the treatment of children have not been originally developed for them. Moreover, the use of unlicensed and off-label medicines is also common among children affected by rare diseases.

Regulatory agencies have implemented multiple initiatives to improve and support drug research in the pediatric population. They have created incentives and obligations for biopharmaceutical companies to perform high quality research and gather more evidence of pediatric safety and efficacy with the intent to bring more effective and safer treatments to children.

At Orphan Reach, we are specialized in conducting studies in children and pediatric rare diseases. We are here to support you with the necessary regulatory requirements for pediatric indications as well as executing your pediatric clinical trials successfully.

Our pediatric research experience includes:

• A proven track record of 147 studies ranging from phase I to phase IV, observational studies across 25+ countries

• 44 studies in pediatric orphan diseases

• Successfully recruited patients globally